Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
Open Access
- 3 December 2022
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-11
Abstract
Background: Use of long-term tobramycin inhalation solution (TIS) has been shown beneficial in cystic fibrosis (CF) and earlier findings also suggest a benefit in non-CF bronchiectasis. We investigated the efficacy and safety of maintenance TIS once daily (OD) in frequent exacerbating bronchiectasis patients chronically infected by different pathogens sensitive for tobramycin. Objective: The primary outcome was the frequency of exacerbations during the 12-month study period. Secondary outcomes were time to first exacerbation, change in lung function and quality of life (QoL), bacterial analysis and safety. Materials/patients: In this multicenter RCT patients aged ≥ 18-year-old were included with confirmed bronchiectasis and ≥ 2 exacerbations in the preceding year. Patients were assigned (1:1) to receive TIS or placebo OD for 1-year.: Results: 58 patients were included of which 52 were analyzed in the mITT analysis. TIS reduced exacerbation frequency with a RR of 0.74 (95% CI 0.49–1.14) (p = 0.15). Within the TIS population a decrease in number of exacerbations was found (2; p = 0.00), which was also seen in the placebo-treated patients (1.5; p = 0.00). In the TIS-treated patients the QoL improved (LRTI-VAS p = 0.02 Leicester Cough p = 0.02) without additional safety concerns. No differences were found for the other secondary outcomes. Conclusion: Long-term TIS OD is a safe treatment modality and showed a non-significant reduced exacerbation frequency of 0.74 as compared to placebo in bronchiectasis patients chronically infected by tobramycin sensitive pathogens. TIS OD may be a potential therapeutic strategy in selected patients with bronchiectasis suffering from a high burden of disease. Trail registration number: The BATTLE study was registered at Clinical trials.gov number: NCT02657473. Date: 13 august 2016.Keywords
Funding Information
- unrestricted grant from TEVA pharmaceutics
This publication has 44 references indexed in Scilit:
- Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis BronchiectasisJAMA, 2013
- Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosisJournal of Cystic Fibrosis, 2012
- Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasisEuropean Respiratory Journal, 2009
- Factors Associated With Lung Function Decline in Adult Patients With Stable Non-Cystic Fibrosis BronchiectasisChest, 2007
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*Chest, 2005
- Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Intermittent Administration of Inhaled Tobramycin in Patients with Cystic FibrosisNew England Journal of Medicine, 1999
- Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasisJournal of Antimicrobial Chemotherapy, 1994
- Efficacy of Aerosolized Tobramycin in Patients with Cystic FibrosisNew England Journal of Medicine, 1993